^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    DUXAP8 (Double Homeobox A Pseudogene 8)

    i
    Other names: DUXAP8, Double Homeobox A Pseudogene 8
    Associations

    News

    Trials
    24d
    Neoadjuvant therapy-associated malignant phenotype score predicts prognosis and highlights the roles of MIF signaling and DUXAP8 in ESCC. (PubMed, Front Immunol)
    NTAMPS enables effective prognostic stratification, predicts potential immunotherapy benefit, and highlights therapeutic vulnerabilities. DUXAP8 was further identified as a candidate molecular driver that may improve ESCC management in the context of neoadjuvant therapy.
    Journal • IO biomarker
    |
    CD74 (CD74 Molecule) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • ACKR3 (Atypical Chemokine Receptor 3) • DUXAP8 (Double Homeobox A Pseudogene 8)
    4ms
    The Role of SLC7A11 in Tumor Progression and the Regulation Mechanisms Involved in Ferroptosis. (PubMed, Cancer Manag Res)
    This study reveals how cancer cells abnormally upregulate SLC7A11 by hijacking multi-level mechanisms, gaining strong antioxidant/anti ferroptotic abilities, which are the core basis for their survival, proliferation, and resistance to treatment. This study also identified SLC7A11 as a convergence point for multiple key pathways, making it an ideal hub target for intervening in cancer and overcoming drug resistance.
    Review • Journal
    |
    BAP1 (BRCA1 Associated Protein 1) • SIRT3 (Sirtuin 3) • SLC7A11 (Solute Carrier Family 7 Member 11) • ATF4 (Activating Transcription Factor 4) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • SOCS2 (Suppressor Of Cytokine Signaling 2) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • DUXAP8 (Double Homeobox A Pseudogene 8) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • METTL3 (Methyltransferase Like 3) • STEAP3 (STEAP3 Metalloreductase) • TCF12 (Transcription Factor 12)
    6ms
    Molecular Mechanisms of Radiation Resistance in Breast Cancer: A Systematic Review of Radiosensitization Strategies. (PubMed, Curr Issues Mol Biol)
    By synthesizing current evidence, this review provides a consolidated resource to guide future mechanistic studies and therapeutic development. This review highlights promising molecular targets and emerging strategies to enhance radiosensitivity and offers a foundation for translational research aimed at improving outcomes in radiation-refractory breast cancer.
    Review • Journal
    |
    MIR21 (MicroRNA 21) • CD24 (CD24 Molecule) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • DUXAP8 (Double Homeobox A Pseudogene 8) • MIR33A (MicroRNA 33a)
    8ms
    Pseudogenes as Potential Diagnostic, Prognostic and Therapeutic Biomarkers in Colorectal Cancer: A Systematic Review. (PubMed, Cancer Rep (Hoboken))
    Our review illuminates the promise of pseudogenes as biomarkers and therapeutic targets, indicating a significant step toward the integration of pseudogenes in the future paradigm of precision medicine for CRC.
    Review • Journal
    |
    CTNNA1 (Catenin Alpha 1) • CDCP1 (CUB Domain Containing Protein 1) • DUXAP8 (Double Homeobox A Pseudogene 8)
    11ms
    Integrative analysis of ceRNA networks and immune cell infiltration in thyroid cancer for enhanced diagnostic and prognostic insights. (PubMed, Sci Rep)
    This study provides new insights into thyroid cancer pathogenesis, suggesting potential molecular markers for early diagnosis and personalized treatment. Integrating ceRNA regulatory mechanisms with immune cell analysis offers a novel perspective on the tumor microenvironment's role in thyroid cancer progression.
    Journal
    |
    DUXAP8 (Double Homeobox A Pseudogene 8)
    12ms
    Evolutionary learning-derived lncRNA signature with biomarker discovery for predicting stage of colon adenocarcinoma. (PubMed, Annu Int Conf IEEE Eng Med Biol Soc)
    Furthermore, the lncRNAs of the signature were prioritized, with the top five being TMEM105, DUXAP8, APCDD1L-DT, PCAT6, and a novel transcript, ENSG00000226308. Furthermore, both Kyoto Encyclopedia of Genes and Genomes pathway and Disease Ontology analyses provided strong support for the viability of this model-independent signature, emphasising ENSG00000226308 as a promising biomarker.
    Journal
    |
    APCDD1L-DT (APCDD1L Divergent Transcript) • DUXAP8 (Double Homeobox A Pseudogene 8) • PCAT6 (Prostate Cancer Associated Transcript 6)
    12ms
    YY1-mediated DUXAP8 facilitates HCC progression via modulating DEPDC1 expression. (PubMed, Clin Exp Med)
    These findings indicate that targeting DUXAP8 could be a new therapeutic strategy for treating HCC. Further research in both preclinical and clinical settings is needed to evaluate its potential as a biomarker and therapeutic target in liver cancer management.
    Journal
    |
    MIR7 (MicroRNA 7) • DUXAP8 (Double Homeobox A Pseudogene 8) • YY1 (YY1 Transcription Factor)
    1year
    Circular RNA circ_0004630 promotes malignancy and glycolysis of nonsmall cell lung cancer by sponging microRNA-1208 and regulating leucine-rich repeat kinase 2 expression. (PubMed, J Biochem Mol Toxicol)
    In conclusion, circ_0004630 knockdown might suppress NSCLC cell proliferation, metastasis, and glycolysis partly by the miR-1208/LRRK2 axis. Our findings hinted at an important theoretical basis for further elucidating the pathogenesis of NSCLC and targeted therapy.
    Journal • Circular RNA
    |
    HK2 (Hexokinase 2) • DUXAP8 (Double Homeobox A Pseudogene 8) • LRRK2 (Leucine Rich Repeat Kinase 2)
    over1year
    The Long Noncoding RNA DUXAP8 Facilitates the Malignant Progression of Colon Cancer via the microRNA-378a-3p/FOXQ1 Axis. (PubMed, Gut Liver)
    DUXAP8 expression was significantly increased in colon cancer, which was associated with lymph node metastasis and unfavorable outcomes in colon cancer patients. DUXAP8 may hasten malignant progression of colon cancer cells through its effects on microRNA-378a-3p/FOXQ1.
    Journal
    |
    DUXAP8 (Double Homeobox A Pseudogene 8) • MIR378A (MicroRNA 378a)
    over1year
    Integrative analysis of anoikis-related genes prognostic signature with immunotherapy and identification of CDKN3 as a key oncogene in lung adenocarcinoma. (PubMed, Int Immunopharmacol)
    The pivotal role of CDKN3 in LUAD was confirmed through qRT-PCR and gene knockout experiments, demonstrating that CDKN3 knockdown inhibits tumor cell proliferation, migration, and invasion. Additionally, we constructed a ceRNA network involving CDKN3/hsa-miR-26a-5p/SNHG6, LINC00665, DUXAP8, and SLC2A1/hsa-miR-218-5p/RNASEH1-AS1, providing new insights for personalized and immune therapy decisions in LUAD patients.
    Journal • IO biomarker
    |
    PLK1 (Polo Like Kinase 1) • CDK3 (Cyclin Dependent Kinase 3) • DUXAP8 (Double Homeobox A Pseudogene 8) • LINC00665 (Long Intergenic Non-Protein Coding RNA 665) • MIR218 (MicroRNA 218) • MIR218-1 (MicroRNA 218-1) • MIR218-2 (MicroRNA 218-2) • MIR26A1 (MicroRNA 26a-1) • SLC2A1 (Solute Carrier Family 2 Member 1)
    over1year
    Radiotherapy and breast cancer: finally, an lncRNA perspective on radiosensitivity and radioresistance. (PubMed, Front Oncol)
    Thus, providing a clear picture of these lncRNAs' underlying RT-relevant molecular mechanisms should help improve overall survival and optimize the best radiation dose for each individual patient. Moreover, in healthy humans, lncRNAs show greater natural expression variation than protein-coding genes, even across individuals, alluding to their exceptional potential for targeting in truly personalized, precision medicine.
    Review • Journal
    |
    NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • HOTAIR (HOX Transcript Antisense RNA) • DUXAP8 (Double Homeobox A Pseudogene 8) • FGD5-AS1 (FGD5 Antisense RNA 1)